Compare Stryker Corporation (SYK) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Xylem, Inc. — how do they compare? Stryker Corporation trades at $277.7 (market cap $106.24B), while Xylem, Inc. trades at $102.41 (market cap $23.81B). The key difference: Stryker Corporation is far larger — about 4.5× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Xylem, Inc. for 50 Days on average.
| SYK | XYL | |
|---|---|---|
Market Cap | $106.24B | $23.81B |
Volume | 2,982,001 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $388.35 | $152.95 |
52-Week Low | $269.75 | $100.92 |
Typical Hold Time | 21 Days | 50 Days |
Enterprise Value | $117.70B | $25.59B |
Dividend Yield | 1.27% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Xylem (XYL) trades at $102.20, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue grew to $9.04B in 2025, with a net income margin of 10.59%, while recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by steady revenue growth and margin expansion, but risks include China weakness and higher debt from recent note offerings. Analyst consensus is mixed with a $149.13 price target, suggesting potential upside, though technical indicators caution near-term pressure. Investment appeal hinges on execution of growth strategies amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
